Targeting cancer with bugs and liposomes: Ready, aim, fire

Cancer Research

Volumn 67, Issue 20, 2007, Pages 9605-9608

  Cheong, Ian ^a   Huang, Xin ^a   Thornton, Katherine ^a   Diaz Jr , Luis A ^a   Zhou, Shibin ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IRINOTECAN; LIPOSOME; PROBIOTIC AGENT; TRIACYLGLYCEROL LIPASE;

CANCER; CANCER CELL; CANCER REGRESSION; CANCER RELAPSE; CANCER THERAPY; CLOSTRIDIUM; CLOSTRIDIUM NOVYI; DRUG FORMULATION; HUMAN; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE;

ANIMALS; CLOSTRIDIUM; DRUG DELIVERY SYSTEMS; HUMANS; LIPASE; LIPOSOMES; MODELS, MOLECULAR; NEOPLASMS;

EID: 35448989290     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-1565     Document Type: Review

References (24)

1. Gregoriadis G, Wills EJ, Swain CP, Tavill AS. Drug-carrier potential of liposomes in cancer chemotherapy. Lancet 1974;1:1313-6.
2. Papahadjopoulos D, Allen TM, Gabizon A, et al. Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. Proc Natl Acad Sci U S A 1991;88:11460-4.
3. Allen TM, Cleland LG. Serum-induced leakage of liposome contents. Biochim Biophys Acta 1980;597:418-26.
4. Horowitz AT, Barenholz Y, Gabizon AA. In vitro cytotoxicity of liposome-encapsulated doxorubicin: dependence on liposome composition and drug release. Biochim Biophys Acta 1992;1109:203-9.
5. Yuan F, Leunig M, Huang SK, Berk DA, Papahadjopoulos D, Jain RK. Microvascular permeability and interstitial penetration of sterically stabilized (stealth) liposomes in a human tumor xenograft. Cancer Res 1994; 54:3352-6.
6. Drummond DC, Meyer O, Hong K, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev 1999;51:691-743.
7. Andresen TL, Jensen SS, Kaasgaard T, Jorgensen K. Triggered activation and release of liposomal prodrugs and drugs in cancer tissue by secretory phospholipase A2. Curr Drug Deliv 2005;2:353-62.
8. White SC, Lorigan P, Margison GP, et al. Phase II study of SPI-77 (sterically stabilised liposomal cisplatin) in advanced non-small-cell lung cancer. Br J Cancer 2006; 95:822-8.
9. Simoes S, Moreira JN, Fonseca C, Duzgunes N, de Lima MC. On the formulation of pH-sensitive liposomes with long circulation times. Adv Drug Deliv Rev 2004;56:947-65.
10. Davidsen J, Vermehren C, Frokjaer S, Mouritsen OG, Jorgensen K. Drug delivery by phospholipase A(2) degradable liposomes. Int J Pharm 2001;214:67-9.
11. Bettegowda C, Dang LH, Abrams R, et al. Overcoming the hypoxic barrier to radiation therapy with anaerobic bacteria. Proc Natl Acad Sci U S A 2003;100:15083-8.
12. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer 2004;4:437-47.
13. Ryan RM, Green J, Lewis CE. Use of bacteria in anticancer therapies. Bioessays 2006;28:84-94.
14. Parker RC, Plummer HC, Siebenmann CO, Chapman MG. Effect of histolyticus infection and toxin on transplantable mouse tumors. Proc Soc Exp Biol Med 1947;66:461.
15. Mose JR, Mose G. Oncolysis by Clostridia. I. Activity of Clostridium butyricum (M-55) and other nonpathogenic clostridia against the Ehrlich carcinoma. Cancer Res 1964;24:212-6.
16. Carey RW, Holland JF, Whang HY, Neter E, Bryant B. Clostridial oncolysis in man. Eur J Cancer 1967;3: 37-46.
17. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001;27:27.
18. Agrawal N, Bettegowda C, Cheong I, et al. Bacteriolytic therapy can generate a potent immune response against experimental tumors. Proc Natl Acad Sci U S A 2004;101:15172-7.
19. Diaz LA, Jr., Cheong I, Foss CA, et al. Pharmacologic and toxicologic evaluation of C. novyi-NT spores. Toxicol Sci 2005;88:562-75.
20. Dang LH, Bettegowda C, Agrawal N, et al. Targeting vascular and avascular compartments of tumors with C. novyi-NT and anti-microtubule agents. Cancer Biol Ther 2004;3:326-37.
21. Cheong I, Huang X, Bettegowda C, et al. A bacterial protein enhances the release and efficacy of liposomal cancer drugs. Science 2006;314:1308-11.
22. Palomo JM, Fuentes M, Fernandez-Lorente G, Mateo C, Guisan JM, Fernandez-Lafuente R. General trend of lipase to self-assemble giving bimolecular aggregates greatly modifies the enzyme functionality. Biomacromolecules 2003;4:1-6.
23. Minton NP, Mauchline ML, Lemmon MJ, et al. Chemotherapeutic tumour targeting using clostridial spores. FEMS Microbiol Rev 1995;17:357-64.
24. Van Mellaert L, Barbe S, Anne J. Clostridium spores as anti-tumour agents. Trends Microbiol 2006;14:190-6.